Physician profile
James A Muse
NPI 1710964077
$5,931.79
in general payments reported to CMS, 2019-2025
19 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,439 · 2020: $423 · 2021: $693 · 2022: $1,324 · 2023: $1,074 · 2024: $558 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,031.13 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $1,670.97 | 2019-2025 | Clareon Panoptix Pro, Argos, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $804.99 | 2019-2021 | |
| Oyster Point Pharma, INC. | $317.94 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $289.60 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $177.08 | 2019-2020 | |
| Dompe US, INC. | $140.97 | 2025 | Oxervate |
| Sight Sciences, INC. | $104.64 | 2019 | |
| Aerie Pharmaceuticals, INC. | $72.42 | 2019-2021 | |
| Allergan, INC. | $63.96 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $61.39 | 2020-2021 | |
| Genmab U.S., INC. | $40.56 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $31.22 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $26.58 | 2024 | Omidria, Rayone Spheric, Rayone Emv |
| Coopervision INC. | $23.63 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $22.81 | 2020 | |
| Abb Con-Cise Optical Group LLC | $20.22 | 2022 | |
| Amgen INC. | $17.88 | 2025 | Tepezza |
| Shire North American Group INC | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Muse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.